The C4XD team - combining decades of Drug Discovery expertise
C4XD has a highly experienced scientific team with expertise across core areas of Drug Discovery. The depth and breadth of knowledge in our team enables us to create industry-leading small molecule programmes which meet critical unmet needs for the industry and patients.
Our technologies -A highly valuable and differentiated platform
We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule generation capabilities, generating differentiated candidates across multiple disease areas.
Conformetrix
Conformetrix enables rational, accelerated 4D structural drug design using experimental data rather than theoretical data. The information provided by Conformetrix provides C4XD’s medicinal chemists with new and unprecedented insights into the behaviour and physical properties of drug molecules to inform design choices. This has the potential to provide more accurate molecule design that is better suited for the intended therapeutic target.
4sight
Working hand-in-hand with Conformetrix, C4XD is pioneering the creation of a specialised visualiser, 4Sight, to enable our scientists to “see” the shape and behaviour of molecules in a revolutionary new way, delivering unprecedented insights and fuelling innovation. Having measured these shapes using Conformetrix, this “4D molecular data” can be visualised and manipulated to inspire the design of drug molecules by allowing our chemists to virtually step inside and ”see” those drug molecules as they are being designed. 4Sight is becoming the central tool for conformational drug design within C4XD, enabling our chemists to make faster progress in developing new candidates that will lead to more effective drugs to meet the medical industry’s needs.
Taxonomy3®
Taxonomy3® is a novel in silico platform technology that utilises proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data. Using human genetic data, Taxonomy3® enables the discovery of targets that cause disease and identifies genetically-defined patient subgroups providing the best starting point for drug discovery, biomarker identification and patient stratification. The resulting drugs have a greater probability of successful clinical development and product realisation.
Alliances play a key role in the development, growth and commercial strategy of our business.
If you would like to discuss opportunities for strategic collaboration or technology partnership with C4XD in the discovery and development of novel targets or small molecule drugs in oncology, neurodegeneration or inflammation, please tell us more in the form below.
